Viking Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Viking Therapeutics (VKTX) Misses Q1 EPS by 6c
May 10, 2017 4:16 PM EDTViking Therapeutics (NASDAQ: VKTX) reported Q1 EPS of ($0.23), $0.06 worse than the analyst estimate of ($0.17).
At March 31, 2017, Viking held cash, cash equivalents and investments totaling $12.3 million. As of April 30, 2017, Viking had 23,925,425 shares of common stock outstanding.
For earnings history and earnings-related data on Viking Therapeutics (VKTX) click here.
... More